Search Within

Isabelle C Riviere

  1. "Center for Hematologic Malignancies"
  2. "Radiology, Department of"
Formats
  1. Journal Article (10)
  2. Meeting Abstract (8)
Groups
  1. Center for Hematologic Malignancies (18)
  2. Department of Medicine (18)
  3. Hematologic Malignancies Research (18)
  4. Hematologic Malignancies, Division of (18)
  5. Radiology, Department of (18)
  6. GSK Faculty (17)

More Groups

People
  1. Michel Sadelain (14)
  2. Renier Brentjens (13)
  3. Elizabeth Halton (7)
  4. Jae Park (7)
  5. Xiuyan Wang (7)
  6. Brigitte Senechal (6)

More People

Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (3)
  6. 2018 (3)

More Years

Publications
  1. Blood (3)
  2. Cancer Discovery (2)
  3. Cancer Research (2)
  4. Journal of Clinical Oncology (2)
  5. Molecular Therapy (2)
  6. Nature Medicine (2)

More Publications

Publishers
  1. American Association for Cancer Research (5)
  2. Nature Publishing Group (5)
  3. American Society of Hematology (3)
  4. American Society of Clinical Oncology (2)
  5. Elsevier Inc. (1)
  6. Massachusetts Medical Society (1)

More Publishers

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results
    Journal Article

    Park, J. H.; Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G.; Dahi, P.; Lin, R. J.; Scordo, M.; Perales, M. A.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab
    Journal Article

    Adusumilli, P. S.; Zauderer, M. G.; RivieĢ€re, I.; Solomon, S. B.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Cheema, W.; Chintala, N. K.; Halton, E.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save
  • A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)
    Meeting Abstract

    O'Cearbhaill, R. E.; Park, J. H.; Halton, E. F.; Diamonte, C. R.; Mead, E.; Lakhman, Y.; Kane, P.; Riviere, I. C.; Brentjens, R. J.
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R.; Zhu, A.; Ngai, D.; McGee, E.; Chintala, N.; Messinger, J.; Cheema, W.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Ngai, D. A.; McGee, E.; Chintala, N. K.; Messinger, J. C.; Vincent, A.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy
    Journal Article

    Smith, E. L.; Mailankody, S.; Staehr, M.; Wang, X.; Senechal, B.; Purdon, T. J.; Daniyan, A. F.; Geyer, M. B.; Goldberg, A. D.; Mead, E.; more...
    Cancer Immunology Research (2019)

    Fulltext@MSK | Save
  • Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia
    Journal Article

    Santomasso, B. D.; Park, J. H.; Salloum, D.; Riviere, I.; Flynn, J.; Mead, E.; Halton, E.; Wang, X.; Senechal, B.; Purdon, T.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save